Skip to main content
Veterinary Medicines

ZOLETIL 50 (25 MG/ML + 25 MG/ML) LYOPHILISATE AND SOLVENT FOR SOLUTION FOR INJECTION FOR DOGS AND CATS

Authorised
  • Tiletamine hydrochloride
  • Zolazepam hydrochloride

Product identification

Medicine name:
ZOLETIL 50 (25 MG/ML + 25 MG/ML) LYOPHILISATE AND SOLVENT FOR SOLUTION FOR INJECTION FOR DOGS AND CATS
Zoletil 25 mg/ml + 25 mg/ml kuiva-aine, kylmäkuivattu, ja liuotin, injektionestettä varten
Active substance:
  • Tiletamine hydrochloride
  • Zolazepam hydrochloride
Target species:
  • Dog
  • Cat
Route of administration:
  • Intramuscular use
  • Intravenous use

Product details

Active substance and strength:
  • Tiletamine hydrochloride
    145.43
    milligram(s)
    /
    1.00
    Bottle
  • Zolazepam hydrochloride
    140.94
    milligram(s)
    /
    1.00
    Bottle
Pharmaceutical form:
  • Lyophilisate and solvent for solution for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QN01AX99
Authorisation status:
  • Valid
Authorised in:
  • Finland
Package description:
  • 1 vial of 675 mg lyophilisate and 1 vial of 5 ml solvent
  • 10 vials of 675 mg lyophilisate and 10 vials of 5 ml solvent

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Finnish Medicines Agency
Authorisation number:
  • 32504
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0283/001
Concerned member states:
  • Finland
  • Ireland
  • Netherlands
  • Poland
  • Sweden

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Finnish (PDF)
Published on: 10/09/2025

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Finnish (PDF)
Published on: 10/09/2025

eu-puar-frv0283001-mr-rpe365-en.pdf

English (PDF)
Published on: 7/01/2026
Download